Trying out Pfizer and BioNTech of the vaccine against omicron 5 it hasn’t even started yet. And who is waiting for what updated vaccine against the sub-variant, it will have to wait several weeks longer than the first predictions September. In fact, the two companies have announced that they will begin clinical trials of the vaccine matched against Omicron’s BA.4 and BA.5 variants in order to commercialize them. not before October. However, should this data also be too optimistic, the feared resurgence of infections after the summer would leave Italians (but not only) in the dark at this point for some time.
MORE INFORMATION
The German company BioNTech today announced the financial results for the second quarter and the first half of 2022, taking stock of the programs it is implementing together with the American Pfizer in the field of Fight against Covid-19. In addition to the bivalent vaccine based on the original virus and on Omicron BA.1, for which the European Medicines Agency EMA has already received the green light, the two companies also want to start clinical studies this month on a targeted bivalent vaccine Omicron BA.4 and BA .5. For both products, “subject to regulatory approval, we expect to begin shipping Omicron-adapted vaccines as early as October,” BioNTech said.
Omicron on vacation Virologist Fazii: “Beware of parties and concerts, the winter will be very hard”
Sales figures BioNTech (down)
In the first half of 2022, the Mainz-based company recorded a 30% increase in sales to EUR 9.57 billion and a 37% increase in net profit to EUR 5.37 billion compared to the first 6 months of 2021. In the second quarter of the year, both revenue and net income show a decline of about 40% compared to the same period last year, to $3.2 billion and $1.67 billion, respectively. BioNTech attributes this to the “dynamic development of the pandemic, which is leading to a postponement of orders and thus to fluctuations in quarterly sales”. However, the group confirms the year-end targets with sales of Covid-19 vaccines between 13 and 17 billion euros.